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In complex diseases like ALS, there are multiple genetic and environmental factors all contributing to disease liability. The genetic factors
causing susceptibility to developing ALS can be considered a spectrum from single genes with large effect sizes causing classical Mendelian ALS,
to genes of smaller effect, producing apparently sporadic disease. We examine the statistical genetic principles that underpin this model and review
what is known about ALS as a disease with complex genetics.
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1.1. What is a complex disease?
Most cases of amyotrophic lateral sclerosis (ALS) are
isolated incidents. When, in 1955, Kurland and Mulder first
provided evidence that in about 10% of cases there was a family
history [1], the natural assumption was that the remaining
sporadic cases did not have a genetic cause. This has to be
viewed on the historical background of the time, when the idea
that ALS might have any genetic component was surprising,
ideas of Mendelian inheritance of disease were mainstream, and
there was no adequate genetic model for non-Mendelian
familial clustering or sporadic disease. We now have a more
detailed and sophisticated understanding of the behaviour of
genes, and it is reasonable to assume that in most if not all cases,
there is a genetic contribution.
The discovery of mutations in SOD1 in 20% of familial cases
[2,3] and between 2 and 7% of sporadic cases [4–8], indicates
that at least some sporadic cases of ALS are genetic. Further
evidence comes from a UK twin study, which examined mono-
and dizygotic twins for concordance, having first eliminated
probands from families already identified with dominant ALS⁎ Corresponding author. Fax: +44 20 7848 5190.
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doi:10.1016/j.bbadis.2006.08.001inheritance. Heritability was defined as h2 =2× [rmz− rdz],
where rmz and rdz are the liability correlations for mono- and
dizygotic twins ranging from 0 (fully non-genetic) to 1 (fully
heritable). Based on these calculations, the heritability of ALS
was shown in this study to be between 38 and 85% [9]. The
authors concluded that “…the finding that between 38% and 85%
of variation in (ALS) is due to inherited factors indicates that
even in so-called sporadic (ALS), with a conservative approach
to analysis of the data, genetic influences are significant.”
Another way to examine the role genetic factors might play
in sporadic ALS is to estimate the relative risk of ALS to
siblings of affected individuals as compared with the population
risk, given the symbol λs. Without detailed population risk data
for ALS from genetic epidemiology, only imperfect guesses are
possible. If it is assumed that since approximately 10% of cases
have a family history, then the risk to a sibling of a sporadic case
with an unknown family history is the risk of having a family
history of ALS×the risk of sharing a dominant allele=1/10×1/
2=1/20. The lifetime risk of developing ALS estimated from
population data and death certificate data as between 1 in 400
and 1 in 1000 [8]. Therefore, a rough estimate of λs is between
(1/20)/(1/400)=20 and (1/20)/(1/1000)=50. The problem with
this approach is that it assumes dominant inheritance, but we
know from many pedigrees that familial clustering may occur
without obvious Mendelian patterns, and these are excluded
from this calculation. Nevertheless, this value for λs does
provide some information.
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aremultiple genetic and environmental factors all contributing to
disease liability. This arises as a direct result of modern genetic
statistical theory, which itself is based on an extended version of
Mendelian genetics. In Mendel's description of genetic
transmission of heritable characters, each “formative element”
was responsible for a single character, and each parent had two
formative elements for each character, transmitting one
randomly to the next generation in gametes. He showed the
transmission of formative elements for different characters was
independent, and that some character traits were dominant to
others, so that the recessive trait was masked in one generation if
the parent had both an element for a dominant and recessive
character simultaneously. When Mendel's ideas were redis-
covered at the turn of the 20th century, the formative elements
were renamed genes, the characters phenotypes, and it was
discovered that one of his laws, that of independent transmission
of elements for different characters, was not always true. Some
phenotypes were linked together in “linkage groups”, in which
transmission of the gene for one phenotype affected the
probability of transmission of a different gene for another
phenotype. We now know the physical basis of linkage groups is
the arrangement of genes in chromosomes, and the distortion by
linkage of transmission frequencies of different characters from
the expected 50:50 is used as a means of disease gene mapping.
Mendelian traits are well recognised, but it is difficult to
explain continuous phenotypes, such as height, on the basis of
single discrete genes. Height has a strong inherited component,
and can be predicted reasonably accurately from parental
heights. A particle theory of genetics needs to be able to explain
this continuous trait without the discontinuities implied by
discrete genes, but there is no such obstacle for a wave theory of
genetics in which waves transmit the genetic information
through generations. There was thus a battle in the early years of
genetics between those who considered genes to be particles,
and those who considered them to be waves. This is not as
ridiculous as it may sound today, as it was thought to be a
logical explanation for the transmission of continuous char-
acters, and was a view held even by William Bateson, the first
professor of genetics in history (who is also responsible for
coining the word “genetics”). The solution came in 1918 when
Fisher, who founded much of modern statistics, showed that
three or more genes each contributing to a trait, but each
following Mendel's laws, would result in a phenotypic
distribution indistinguishable from a normal distribution,
particularly if there was also an environmental contribution.
This is because the alleles for each gene occur in pairs in each
individual, and the phenotypic traits therefore follow the
binomial distribution. The binomial distribution approximates
the normal distribution as n increases, and with n>2, the
approximation is quite good. (For example, three loci with
equally frequent alleles A and a, B and b, and C and c, in which
capital alleles increase a trait, say IQ, by 5 and small case alleles
decrease the trait by 5, result in IQs of 70, 80, 90, 100, 110, 120
and 130 with frequencies of 1:6:15:20:15:6:1). It was therefore
possible to explain Mendelian traits and continuous traits using
straightforward statistics applied to Mendel's laws.Unfortunately, this approach still does not explain discrete
traits showing familial clustering but without Mendelian
inheritance. This was modelled successfully in 1981 with the
so-called threshold liability model [10]. In this explanation, the
liability to disease rather than the phenotype itself, is what is
normally distributed (as in the three genes or more model), but
disease only occurs once a critical threshold of liability is
crossed. If the cumulative disease susceptibility burden is
sufficient then the individual develops disease. This is
classically illustrated with cleft lip and palate, which shows
familial clustering but is not Mendelian. The “hidden” normally
distributed phenotype, liability to cleft lip and palate, is in fact
the speed and timing of fusion of the palatal plates. The exact
speed at which they come together is unimportant so long as
they meet before a critical developmental stage. This model
transforms a continuous trait back into a binary phenotype/no
phenotype discrete trait. The result predicted is familial
clustering, but because of smaller family sizes and poor
knowledge of extended families, cases can appear sporadic.
We now therefore have three models explaining three modes
of genetic disease transmission: Mendelian—where discrete
traits are inherited in a predictable fashion, the polygenic model
for continuous traits, and the liability threshold model for a
discrete trait with familial clustering which is not inherited in a
Mendelian fashion. Other factors increasing the complexity of
genetic predisposition to disease of which we are currently
aware are: the multiple effects of single genes (pleiotropy), the
interaction of multiple genes with each other (epistasis), the
interaction of genes with environmental factors, splice variants
of genes, variations in copy number, and post translational
protein modification, but there will undoubtedly be others
discovered in the future.
There is therefore complexity from the number and effect
size of genes contributing to disease risk. There is a further layer
of complexity at the level of phenotypic expression because the
expression of one gene can alter the expression of another at
transcription, at the level of molecular cell machinery, or based
on the cell type, organ or system it is expressed in, and so a
phenotype is rarely the product of a single gene, even if it seems
so at first. Modifying genes may enhance or reduce a
phenotype, produce novel phenotypes, or mask the effect of a
disease gene, to produce an organism that resembles the wild-
type. In Mendelian diseases, this may be manifested as reduced
penetrance, for example, age or sex-dependent penetrance.
Even when environmental factors are the same, traits which are
inherited in a dominant manner on one genetic background can
display recessive or co-dominant inheritance on another. Many
other modifier effects are recognised, but all are examples of
gene–gene or multiple gene–environment interactions. The
“one gene, one trait”model of disease can therefore be regarded
as too simple for any complete description of disease risk, even
though it is useful for identifying genes for Mendelian diseases.
2. ALS susceptibility
The liability threshold model is now generally accepted as
the best description and explanation of the behaviour of
975C.L. Simpson, A. Al-Chalabi / Biochimica et Biophysica Acta 1762 (2006) 973–985complex diseases. Susceptibility to developing ALS can
therefore be considered a spectrum from single genes with
large effect sizes causing classical Mendelian ALS, to multiple
genes of smaller effect, producing apparently sporadic disease.
Those genetic causes of ALS so far identified and robustly
replicated have all been in genes causing disease inherited in a
classical Mendelian fashion, giving the appearance that all
genetic ALS is familial and Mendelian. This is to some extent a
self-fulfilling prophecy, since the gene-hunting techniques
available at first required large pedigrees with clear inheritance
patterns. What is now required is an approach to find the small
effect genes that contribute together with each other and
environmental factors to cause ALS. Hunting for such genes is
possible using case-control association studies, but in the past
these have been hampered by the large numbers of genetic
markers and samples required to attain sufficient power. Until
recently therefore, most studies have confined themselves to
examining candidate genes selected because of structure,
function or similarity to known genes. The problem is that in
ALS little is known about the disease mechanism, making
candidate gene selection difficult, haphazard, and the biased
choice of a researcher. As a result, many studies performed to
date have not found association, and only a few of those that
have found association have been replicated.
For diseases such as ALS, with late onset and short survival,
association mapping of disease genes in unrelated individuals is
an important approach because obtaining the number of cases
required for sufficient power in family-based studies is
problematic. Genome-wide association studies, which use a
strategy similar to linkage scans, uses large numbers of
informative markers to identify association between allelic
variants and disease. This is the ideal approach for diseases like
ALS where the etiology remains largely unknown as it makes no
a priori assumptions about the location of the variants of interest.
However, the extent of linkage disequilibrium in unrelated
samples is small and this means that very dense marker sets must
be used on large sample sizes in order to generate sufficient
power to detect association. This has meant that the costs and
workload involved in such studies was unfeasible. To get around
this problem, most studies have chosen a candidate gene
approach where candidates are chosen based on hypotheses of
disease causation. Unfortunately, such studies have so far been
inconsistent and frequently underpowered. Here we review
some of the most salient studies to date.
2.1. Apolipoprotein E
The difficulties in unravelling the genetic architecture of
sporadic ALS are well illustrated by Apolipoprotein E (APOE)
which has been studied both as a risk factor for ALS and as a
modifier of various phenotypic aspects. APOE is one of the
molecules responsible for the chaperoning of cholesterol
through the bloodstream. It is polymorphic in the general
population, with two SNPs forming three major haplotypes
named as alleles, E2, E3 and E4 (the fourth, E1, does not tend to
occur) [11]. Genetic variants of APOE are implicated in many
abnormalities of blood lipids and cardiovascular disease, asmight be expected, but have also been shown to play a role in
neurological disease. For example, the E4 allele has been
associated with increased risk and earlier disease onset in late-
onset familial and sporadic Alzheimer's disease [12], faster
progression and earlier disease onset in multiple sclerosis [13]
and poor prognosis after traumatic brain injury [14–18]. Similar
studies in ALS have led to contradictory results. Some have
shown no association between any of the APOE alleles and
either susceptibility, or the phenotypes age at onset, bulbar onset
or survival from symptom onset [19–22], while others have
found a relationship between possession of the E4 allele and the
phenotypes of bulbar onset [23,24] and shorter survival [25].
Although there have been many studies, the current opinion is
that there is no effect of APOE on ALS risk or phenotype, but
this cannot be certain. The problem with case-control studies is
that they are prone to false positive association if cases and
controls are not well matched. This is because differences
between the two groups are not due to disease status alone, but
also to other hidden attributes. To deal with this problem, proper
matching of cases and controls is essential, and one way of
doing this is to use family members [26]. The control can either
be an unaffected sibling or the non-transmitted parental alleles.
One such method is the transmission disequilibrium test [27],
which is a joint test of linkage and association performed by
examining the probability of transmission of a marker gene
from parents to an affected offspring. If this probability is
greater than the expectation of 0.5, it can be concluded that the
marker is associated with disease. This approach has been used
for example, to examine APOE and age of onset as a
quantitative trait in ALS, showing that the age of onset of
ALS for carriers of the E2 allele is about 3 years later than that
for the other alleles [28].
The contradictory nature of the studies into APOE demon-
strates the importance of large sample sizes, well matched
controls and stringent p-values, for reproducible, believable
associations. The key to association studies is replication of
results, and without this, we should be skeptical about findings.
We will now discuss a few other association studies in some
detail, but for a full summary, the reader is referred to Table 1.
2.2. SOD1
ALS was first linked to chromosome 21 in 1991 [3] and
mutations in SOD1 identified as accounting for 20% of familial
cases [2] and 2–7% of sporadic cases [8]. Here we will only
discuss its role as it relates to sporadic ALS.
SOD1 is an abundant cytosolic homodimeric protein, and
each subunit contains copper and zinc ions in the active site. Its
normal function is to reduce the superoxide radical to hydrogen
peroxide, which can then be broken down by catalase,
preventing oxidative damage. There are two other SOD
molecules: SOD2 is a manganese SOD located in mitochondria
and SOD3 is an extracellular SOD which also binds copper and
zinc. Over 100 mutations in SOD1 have now been discovered,
mostly heterozygous missense point mutations [29,30]. Un-
usually for an enzyme, all mutations are autosomal dominant
except for the D90A mutation which can be dominant or
Table 1
A summary of association studies in ALS
Gene Description Reason for Investigation Significance References
ALAD D-Aminolevulinic
Acid Dehydratase
Lead exposure associated with ALS
ALAD is involved in haem synthesis in
erythrocytes
No association [107,108]
ALS2 Alsin Causes autosomal recessive juvenile ALS
(ALS2).
No association [109–113]
ANG Angiogenin ANG is functionally similar to VEGF Association found in Scottish
and Irish populations
[114,115]
APEX Apurinic
endonuclease
Defective DNA repair hypothesis of ALS etiology May have small role but
not major factor
[115]
APOE Apolipoprotein E Implicated in several other neurodegenerative disorders Not associated with susceptibility.
May be associated with age of
onset, presentation and survival
[19,20,23–25]
AR Androgen receptor Causes Kennedy spinal and bulbar muscular atrophy. No association [116]
CCS Copper chaperone for
superoxide dismutase
Gene responsible for copper insertion into SOD1 No association [117]
CNTF Ciliary neurotrophic factor Mice lacking CNTF develop mild, progressive motor
neuron loss
Contradictory results [47,49,50,53,118,119]
CYP2D6 Cytochrome p450,
subfamily IID,
polypeptide 6
Hypothesized poor metabolism of xenobiotics as
risk factor
One reported association,
not replicable
[120,121]
DCTN1 Dynactin Disruption of dynein/dynactin complex produces
motor neuron disease phenotype in mice
One reported association,
not yet replicated
[95]
DNCH1 Dynein heavy chain Mutations in Dnch1 result in progressive motor neuron
degeneration in heterozygous mice, homozygotes also
have Lewy-like inclusion bodies,
No association [90,91,95]
EAAT2 Excitatory amino acid
transporter 2
Excitotoxicity hypothesized to result in motor neuron
degeneration
No association [122–128]
HexA Hexosaminidase A HexA deficiency causes accumulation of ganglioside
GM2 leads to neurodegeneration causing wide spectrum
of neurological diseases
Occasionally causes rare
ALS-like syndrome
[129]
HFE Haemochromatosis Oxidative stress is hypothesized to be implicated in
neurodegeneration and misregulation of iron induces
oxidative stress. Also, abnormal iron levels found in
spinal cords of ALS patients
Contradictory results [130,131]
LIF Leukaemia inhibitory factor LIF is same cytokine family as CNTF, involved in
motor neuron survival
One reported association,
not yet replicated
[132,133]
LOX Lysyl oxidase LOX is a copper containing enzyme and copper-
induced cytotoxicity is a hypothetical mechanism of
motor neuron degeneration
No association [134]
MAO-B Monoamine oxidase B MAO-B generates free radicals and these are
implicated in neuronal damage
Association with age at
onset modification reported,
not yet replicated
[135]
MAPT Microtubule-associated
protein tau
Microtubule-associated protein tau involved in other
neurodegenerative diseases and Guam variant of ALS
has neurofibrillary tangles containing aggregates of tau
Association reported but
p values were weak
[136,137]
Mito Mitochondrial
DNA
deletions
Accumulation of mitochondrial DNA mutations
associated with aging development of degenerative
diseases. In ALS, abnormal mitochondria are often
found in spinal motor neurons
Associations reported, but all
studies very small
[138–144]
NAIP Neuronal apoptosis inhibitory
protein
NAIP involved in related disease, spinal muscular
atrophy
No association. Mutations
in NAIP now considered
specific for SMA
[99,101,102,106]
ND2 Subunit 2 of
mitochondrial NADH
dehydrogenase
(Complex I)
Expression of ND2 found in Alzheimer's brains No association [145]
NEFH Neurofilament,
heavy chain
Neurofilament accumulation is a hallmark of ALS Significant association, tail domain
deletions present in ∼1% ALS
patients, not in controls. Findings
have replicated in several studies
[78–81,133,146]
PRPH peripherin Transgenic mice over-expressing peripherin develop
motor neuron degeneration
Few mutations found, not a
common cause of ALS
[86,87]
PSEN1 presenilin-1 PSEN1 involved in apoptosis, a postulated mechanism
for neuronal death
Weak association found, small
study, not replicated
[147]
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Table 1 (continued)
Gene Description Reason for Investigation Significance References
PVR Poliovirus receptor Poliovirus attacks motor neurons selectively,
enteroviral nucleic acids found in spinal cord
of ALS patients
Association with lower motor
neuron disease found in one
small study, not yet replicated
[148]
SETX Senataxin Mutations in SETX cause autosomal dominant
juvenile ALS (ALS4)
New familial gene, not yet tested
in sporadics
[149]
SMN1/2 Survival of motor
neuron 1/2
Deletions and mutations of SMN genes cause spinal
muscular atrophy
SMN genotypes which reduce
SMN protein levels associated
with sporadic ALS
[98,104,105,150]
Spastin and
paraplegin
Hereditary spastic
paraparesis
Mutations in spastin and paraplegin are the most
common causes of hereditary spastic paraparesis
One case reported of young onset,
slowly progressive upper and lower
motor neuron syndrome with spastin
mutation. No association with
paraplegin
[151,152]
SNCG Persyn Persyn is a member of the synuclein family,
γ-synuclein. Mutations in α-synuclein found in
Parkinson's disease
No association [153]
SOD1 Cu/Zn superoxide
dismutase 1
Mutations in SOD1 account for 20% of familial ALS. 2–7% sporadic cases have
mutations
[2,3,5,7,8,29]
SOD2 Manganese
superoxide dismutase
SOD2 is a related protein of SOD1, found in
mitochondria
No association [154]
VAPB Vesicle-associated
membrane protein-associated
protein B
Mutations in VAPB cause an autosomal dominant,
slowly progressive ALS (ALS8)
New familial gene, not yet
tested in sporadics
[155]
VDR Vitamin D receptor Lead exposure associated with ALS. Vitamin D can
affect lead absorption and distribution
Not significant [107,108]
VEGF Vascular endothelial
growth factor
Susceptibility Association found in
some populations
[59–61,156]
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individual, and is polymorphic in parts of Scandinavia [31–
33]. Mutant SOD1 enzyme activities vary, some being inactive
(e.g. H46R) and others near normal (e.g. G93A). There seems to
be no correlation between disease onset or duration and mutant
SOD1 ability to scavenge superoxide, half-life, solubility,
resistance to proteolytic degradation, aggregation potential, or
affinity for copper, and the evidence is for a gain of a novel toxic
function. How such a diverse range of mutations can result in a
novel function producing the same relatively homogeneous
phenotype remains a mystery.
2.3. Clinical features of SOD1 ALS
SOD1 ALS is clinically indistinguishable from sporadic
ALS. The mean age of onset is consistently 46 to 47 years
regardless of the underlying mutation, and in general, there is
90% penetrance by age 70. The mean duration for familial ALS
in general is 3–6 years and there is little difference for familial
ALS caused by SOD1 mutation. It is not unusual for there to be
predominantly lower motor neuron signs, at least to start with.
Bulbar onset is unusual and is usually associated with a later
onset. There may occasionally be extra-motor symptoms
including dementia, autonomic failure, supranuclear extra-
ocular muscle weakness and bladder dysfunction.
2.4. Phenotype variation in SOD1 ALS
The phenotype observed in SOD1-mediated familial ALS is
highly variable, with age-at-onset, severity and survival allvarying wildly, but there is some genotype–phenotype correla-
tion for a few mutations. A4V is the most common ALS-
associated SOD1 mutation in North America, accounting for
50% of all mutations [34]. Patients with this mutation have a
common phenotype with rapid progression and death occurring
at 1.4 years, rather than the 3–5 years which is more typical in
other SOD1 mutations [35]. There are other SOD1 mutations
with specific phenotype associations, such as I113Twhich has a
much older mean age-at-onset compared with other SOD1
mutations, G37R, which is associated with a significantly
earlier age-at-onset and longer survival, L38V, which is
associated with earlier age-at-onset and G41D and G93C,
which are associated with longer survival [35]. Most mutations
do not relate to a single phenotype and the wide range of
mutations in SOD1 cannot account for this variability as clinical
variation can be observed in members of the same family
[29,36]. This suggests that environmental and genetic factors
are modifying the phenotype. Many mutations also show
incomplete penetrance. The picture is therefore complicated
even for the relatively simple situation of a single, large effect,
autosomal dominant gene.
The D90A mutation is a case in point. Homozygous
affected individuals are more frequent in the Torne Valley, a
remote part of northern Sweden and Finland, whereas
heterozygous affected are generally from other parts of the
world, including southern Sweden, the UK, Belgium and
France. The Torne Valley homozygotes have a predictable and
relatively benign phenotype, with a generally ascending spastic
weakness, long survival and occasional extramotor involve-
ment. Heterozygous affected have a more variable phenotype
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mutations. The D90A mutation has been shown to have a
single founder, about 500 generations ago, with the Torne
Valley families becoming isolated approximately 50 genera-
tions ago [33,37]. One explanation for these phenotypic
differences is that D90A is normally a dominant mutation,
consistent with other SOD1 mutations, but that some
protective factor tightly linked to SOD1 is found only in the
Torne Valley families. Therefore, two copies of the D90A
mutation would be required for disease development. Inves-
tigation of sequence variants in genes surrounding the SOD1
locus has not found any variants which can account for the
differences in phenotype [38,39]. An alternative explanation is
that all SOD1 mutations act in an additive fashion to increase
the risk of developing ALS. Most mutations would have a
large effect size, and so only a small contribution from other
genetic or environmental factors would be needed in order to
cause disease. This would account for the autosomal dominant
inheritance and age-dependant penetrance. If the effect size for
D90A was smaller than the other SOD1 mutations, but still
more than 50% of the liability threshold, heterozygous
individuals would only develop ALS if they also had a
number of other risk factors contributing enough to the disease
burden. A second copy of the mutation would also be
sufficient to cause ALS. This would explain the pattern of
recessive inheritance in the Torne Valley families and would
also explain the existence of some affected heterozygotes with
no family history of ALS. Some families living in particular
regions with strong contributory factors would inherit the
mutation phenotype as a dominant trait. This has been seen in
a French family, which apparently had dominant D90A-
mediated ALS [32], but was later shown to have a compound
heterozygosity for a second SOD1 mutation [40]. This
demonstrates that SOD1 mutations may themselves be part
of a general contribution to disease liability.
2.5. Ciliary neurotrophic factor
Ciliary neurotrophic factor (CNTF) was first isolated from
chick ciliary ganglia and shown to promote the survival of
parasympathetic neurons in vitro [41]. It has been shown to
have trophic and differentiating effects on many different neural
cell types [42–45]. For example, Progressive Motor Neurono-
pathy (pmn) is a naturally occurring autosomal recessive
mutation found in mice which resembles spinal muscular
atrophy in humans. When mice homozygous for the pmn
mutation were treated with CNTF at symptom onset, they
showed prolonged survival, improved motor function and fewer
of the cellular changes associated with neurodegeneration [46].
Conversely, inactivation of the mouse CNTF gene is not lethal,
but the mice develop progressive muscle atrophy, loss of motor
neurons and muscle weakness [47], suggesting that in mice at
least, CNTF expression is not essential for spinal motor neuron
development but is necessary for postnatal neuronal survival.
These results suggest a possible role for CNTF abnormalities
in human neurological and psychiatric disorders. Approxi-
mately 2% of the human population are homozygous formutations that inactivate CNTF. So far investigations of such
mutations in unipolar affective disorder, schizophrenia and
Alzheimer's disease have failed to find any association [48].
Similarly, in ALS, most formal studies of null CNTF mutations
have not found association [49–51]. There is however a report
of a family with ALS due to SOD1 mutation, one member of
which was homozygous null for CNTF and had a much younger
onset and more rapid disease course than other affected family
members [52]. It was suggested that CNTF was modifying age
of onset in this family. This was supported by the observation
that mice transgenic for the G93A SOD1 mutation crossed with
homozygous null CNTF mice had earlier disease onset than the
wild type, but disease duration was unaffected. Although this is
a compelling argument, the pattern of SOD1 and CNTF
inheritance in this family can equally be explained by chance. A
later study of 400 ALS patients found no association between
null mutations in CNTF and age of onset, disease progression,
survival or clinical presentation [53]. It is therefore difficult to
conclude that CNTF is a major modifier of ALS phenotype
without further evidence.
2.6. Vascular endothelial growth factor and angiogenin
Vascular endothelial growth factor (VEGF) regulates the
growth of new blood vessels and induces vascular permeability.
However, VEGF also has additional non-vascular functions.
Neuronal axon pathfinding is mediated by semaphorins acting
on neuropilin receptors. These receptors are also acted on by
various members of the VEGF family [54,55], which implies a
role for VEGF in neuronal growth and repair. Additionally,
VEGF receptors have been discovered on neurons and
astrocytes [56] and on the neural progenitor cells of the retina
[57], which suggests that VEGF can act in a neurotrophic and
neuroprotective role in the central and peripheral nervous
system. Other pro-angiogenic growth factors such as basic
fibroblast growth factor (bFGF) and platelet derived growth
factor (PDGF) have also been shown to be neurotrophic [58]. It
is perhaps not surprising therefore that transgenic mice with a
deletion of the hypoxia-response element in the VEGF promoter
(Vegfaδ/δ) develop a progressive motor neuron degeneration at
about 5 months of age, reminiscent of ALS [59] (although this
was a surprise when first discovered). These mice have reduced
levels of VEGF in neural tissue, and induction of VEGF
expression by hypoxia in the spinal cord and the brain is
diminished.
Following the initial findings in mice, a large multi-centre
study was performed to analyse the equivalent region in
humans. SNPs and SNP haplotypes were associated with ALS
in the Swedish population, Belgian population and a UK
population from the Birmingham area. A fourth population
from London in the UK did not show an association. In a meta-
analysis of the separate centre studies, individuals homozygous
for two haplotypes in the VEGF promoter/leader sequence were
found to have 1.8 times increased risk of developing ALS [60].
This is one of the largest association studies in ALS to date and
included almost 2000 people. It provides good evidence for a
true association of VEGF haplotype and susceptibility to ALS,
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the findings.
Other studies have been unable to replicate these results [61–
64], which may reflect the small sizes of these studies compared
to the original study. A possible weak association with affection
status and sex has been found [64] and it has been hypothesized
that high female to male ratios are needed to detect the
association, since this study and the London population in the
original study failed to show an association, and they both had
low female to male ratios compared to the other populations
examined. Further study will have to be done to show whether
this is a real association or merely coincidence. Nevertheless,
these same haplotypes are associated with a decrease in levels of
circulating VEGF and reduction in gene transcription and
therefore have a functional effect on the neuronal response to
hypoxia. Given the findings in mice, this supports a role in
humans, but further studies are required.
A related protein, also involved in the response to hypoxia is
angiogenin. This protein is interesting because its gene lies
close to that of APEX nuclease which has been implicated in
ALS (Table 1), and it is therefore possible that the signal in
APEX nuclease is in fact a result of linkage disequilibrium with
a true functional variant in angiogenin (ANG). Angiogenin is
functionally similar to VEGF, is an inducer of neovascularisa-
tion and is required for cell proliferation induced by other
angiogenic proteins such as VEGF [65]. A common haplotype
associated with a mutation in the angiogenin gene has been
identified in patients of Scottish and Irish descent, although an
association was not found in other populations studied [65].
Seven missense mutations were identified in both familial and
sporadic ALS patients, of which five were within highly
conserved residues in catalytic sites of the ANG protein,
suggesting a direct effect on the activity of ANG. There is an
interaction between ANG and VEGF, in that downregulation of
angiogenin reduces VEGF-induced rRNA transcription, and
inhibition of nuclear translocation of ANG completely knocks
out the angiogenic activity of VEGF. As described above, mice
lacking VEGF are known to develop motor neuron degenera-
tion [59] and this provides a possible hypothesis of disease
causation for ANG mutations. Interestingly, the effect of ANG
mutations seem to be population specific, being found mainly in
those with Irish/Scottish ancestry, and it will be important to
discover the modifying factors that contribute to disease risk to
produce this pattern.
2.7. Neurofilaments and peripherin
One of the characteristic pathological findings in ALS is the
presence of accumulations of neurofilaments in the perikarya
and proximal axons [66–69]. Neurofilaments are a type of
intermediate filament found in neural cells and are thought to
play a critical role in supporting the long thin axonal processes.
Neurofilaments are classified by size as light (NEFL), medium
(NEFM) and heavy (NEFH) chains, and assemble as hetero-
polymers with a NEFL core with NEFM and NEFH arranged
around the outside. Chains are distinguished on the basis of tail
length, with NEFM and NEFH containing a repeating lysine–serine–proline (KSP) motif which can be variably phosphory-
lated. Tail phosphorylation causes extension and electrostatic
repulsion and is thought to regulate axonal calibre and
interaction with other cytoskeletal components.
Overexpression of the mouse light chain neurofilament gene,
NEFL and the human heavy chain neurofilament gene, NEFH,
had been shown to cause a neurodegenerative syndrome in
transgenic mice [70,71] leading to the hypothesis that over-
expression of neurofilaments could be an important part of
human disease development. This view was supported by the
evidence that disruption of the neurofilament genes to the point
where neurofilaments were completely absent protected mice
containing the human G85R SOD1 transgene from neurode-
generation [72]. The authors hypothesized that although
neurofilaments are important for neuronal survival in develop-
ment, they contribute to the vulnerability of motor neurons to
the toxic effect of G85R SOD1.
When transgenic mice containing mutant SOD1 were
crossed with transgenic mice overexpressing the heavy and
light chain neurofilament gene [73–75], surprisingly these
double transgenic mice had a large improvement in their
lifespans and analysis of the spinal cord of 1 year old mice
revealed that the massive neurodegeneration typically seen in
mutant SOD1 mice was markedly less in double transgenic
littermates [73–75]. This confusing picture of neurofilaments in
SOD1-mediated ALS suggests that more studies are needed in
this area.
Studies of neurofilament mutations in ALS patients have
been suggestive of a primary but not major role in ALS. The
first of these identified two common variants of the NEFH tail,
differing in KSP repeat length, neither variant associated with
susceptibility to ALS [76]. A further study by the same group
found a codon deletion in five affected individuals and no
controls [77]. Two family based studies did not find linkage of
the region or mutation in about a hundred patients, suggesting
that NEFH variants are not a cause of familial ALS [78,79]. A
study of sporadic patients from Scandinavia and the UK
identified several mutations in NEFH, accounting for approxi-
mately 1% of sporadic ALS cases, and this study also identified
a deletion in an individual with familial ALS, although it was
not possible to tell if it segregated with disease in this family
[80]. Interestingly, all were deletions of multiples of whole
repeat motifs, and this pattern also applied to an 84 bp insertion
found in a different study [81]. Disease-associated deletions are
always paired with the longer wild-type NEFH allele, and the
insertion paired with the shorter wild-type NEFH allele. It is
possible that the difference in tail lengths is one of the factors
increasing susceptibility to ALS, but the picture remains
unclear, with the latest study unable to positively confirm the
association for NEFH or the other neurofilament subunits [82].
NEFL mutations have been found in a related motor neuron
disease, Charcot–Marie–Tooth type 2E [83,84], a hereditary
motor and sensory neuropathy.
Peripherin is another type of intermediate filament, prefer-
entially expressed in the peripheral nervous system [85]. A
frameshift mutation has been identified in one ALS patient [86],
and this was not found in controls. This mutation produced a
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cultures was unable to self-assemble into neurofilament
structures and disrupted NEFL and NEFM assembly into the
intermediate filament network. One other mutation has been
identified in a patient with sporadic ALS [87]. Immunocyto-
chemistry revealed unusual large aggregates within the spinal
motor neurons which contained both neurofilaments and
peripherin. Transfected into mice, the mutant protein sponta-
neously formed aggregates, implying that the mutation was
interfering with peripherin assembly.
These studies suggest that genetic variants of intermediate
filaments may be a primary cause or contribute significantly
towards susceptibility in a small proportion of cases.
2.8. Dynein and dynactin
The neurofilament network is a key part of the axonal
transport system, and the pathological findings in ALS taken
with the potential primary role of neurofilament mutations,
suggest that impairment of axonal transport may be an
important step in ALS pathogenesis. In keeping with this,
SOD1 mouse models of ALS display impaired retrograde
axonal transport [88]. This form of transport is mediated by
dyneins, which are microtubule-activated ATPases responsible
for transport towards the (−) end of microtubules. They are very
large multimeric proteins composed of two or three heavy
chains complexed with variable numbers of intermediate and
light chains, and require a complex of microtubule-binding
proteins that link the cargo to the microtubules. One such
complex is dynactin, a well characterised set of at least 8
different subunits, enhancing dynein-dependent motility.
Homozygous loss of the cytoplasmic dynein heavy chain 1
gene (DNCHC1) is often lethal at an early stage of
embryogenesis in mice, but heterozygotes are normal [89].
Mutagenesis of this gene has produced two mouse phenotypes
with age-related progressive loss of muscle tone and motor
ability. Such mutations specifically result in defective fast
retrograde transport only observed in alpha motor neurons.
Homozygous mice surviving to birth are severely affected and
cannot feed or move, dying within 24 h of birth [90]. Lewy-like
inclusion bodies and significant loss of spinal anterior horn cells
can be observed in homozygotes in utero, and these are similar
pathological findings to those observed in human ALS and
other motor neuron degeneration phenotypes. Despite this, no
mutations in human dynein have been found in ALS [91]
although mutant SOD1 has been shown to interact with the
dynein/dynactin complex [92]. The story for dynactin is
however a little different. InDrosophila, disrupting the dynactin
complex increases the frequency and extent of synaptic
retraction events at the neuromuscular junction [93] and this
suggests that dynactin is critical for synapse stabilisation.
Transgenic mice overexpressing dynamitin, one of the dynactin
complex subunits, show inhibited retrograde axonal transport,
caused by disruption of the dynein–dynactin complex [94].
These mice develop a late-onset, slowly progressing neurode-
generation similar to human ALS. Dynactin mutations have
now been identified in a few familial and sporadic ALS patients[95–97] and it seems likely that genetic variants which impair
axonal transport increase susceptibility to ALS.
2.9. SMN genes and copy number variation in complex
diseases
Childhood-onset spinal muscular atrophy (SMA) is a
disease confined to lower motor neurons and is caused by
deletions or mutations in the Survival Motor Neuron (SMN)
gene. There are two copies of SMN in humans; SMA is only
caused by mutations or deletions in SMN1, but SMN2 copy
number is associated with modification of disease severity.
Because of the similarities between SMA and ALS, various
studies have examined the relationship between the SMN
genes and ALS. Studies looking for mutations in SMN1 in
ALS patients have not found any association [98–102].
Studies of SMN2 deletion have shown conflicting results
[103,104] but these were small studies and it is therefore
difficult to draw firm conclusions. Because the chromosome 5
region containing the SMN genes is duplicated, some studies
have examined copy number. These have shown that copy
number variation that reduces the amount of SMN protein
expressed is associated with ALS susceptibility and increased
disease severity [98,105]. Further evidence in support of this
comes from studies of transgenic SOD1-G86R mice crossbred
onto differing genetic backgrounds, which show significantly
altered age at onset on some backgrounds compared to others
[106]. This effect has been linked to a region of the mouse
genome syntenic to human chromosome 5 and which contains
the mouse SMN gene.
Both SMN1 and SMN2 contribute to total SMN protein
levels. However, SMN2 is less efficient than SMN1 and
produces only 20% of SMN transcripts. To assess copy number
impact on total SMN protein levels, it is possible to estimate
SMN protein level using a formula derived by Veldink and
colleagues: SMN protein level=SMN1 copy number + 0.20 ×
SMN2 copy number [105]. For example, 2 copies of SMN1 and
2 copies of SMN2 would give an SMN level of 2.4. Patients
with ALS have been shown to have significantly less total SMN
protein than controls, the majority having an SMN level ≤2.2,
whereas most controls had a level ≥2.4.
Copy number variation at the SMN locus may therefore be
important in ALS, and copy number in general is being
increasingly recognised as a significant cause of genetic disease.
3. Conclusion
The number of replicated association findings in ALS remains
depressingly small. No obvious themes of involved proteins have
yet emerged, but this remains the hope. Although we continue to
make small advances in our understanding of the genetic factors
which contribute to disease risk or modify disease phenotype in
ALS, there is a great need for large-scale association studies.
Despite many years of research and the discovery of a number of
genes which cause familial ALS, these still only account for a
very small proportion of cases. Candidate gene association
studies are limited by their narrow focus on small regions of the
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uncertain hypotheses of the biological basis of the disease, or by
genes already known to cause familial ALS and related diseases.
The techniques for genotyping large numbers of genetic markers
in a feasible time and at a reasonable cost are now with us.
Genome-wide association studies are now a realistic approach for
the investigation of the genetic component to sporadic ALS.
Recent studies into diseases such as age related macular
degeneration, multiple sclerosis, and rheumatoid arthritis show
that these sorts of association studies can find robust, replicable
associations. These represent our best hope of elucidating
mechanisms that underlie the disease and provide new targets
for palliative, preventative and curative treatments.References
[1] L.T. Kurland, D.W. Mulder, Epidemiologic investigations of amyotrophic
lateral sclerosis. 2. Familial aggregations indicative of dominant
inheritance, I Neurology 5 (1955) 182–196.
[2] D.R. Rosen, T. Siddique, D. Patterson, D.A. Figlewicz, P. Sapp, A.
Hentati, D. Donaldson, J. Goto, J.P. O'Regan, H.X. Deng, et al.,
Mutations in Cu/Zn superoxide dismutase gene are associated with
familial amyotrophic lateral sclerosis, Nature 362 (1993) 59–62.
[3] T. Siddique, D.A. Figlewicz, M.A. Pericak-Vance, J.L. Haines, G.
Rouleau, A.J. Jeffers, P. Sapp, W.Y. Hung, J. Bebout, D. McKenna-
Yasek, et al., Linkage of a gene causing familial amyotrophic lateral
sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity,
N. Engl. J. Med. 324 (1991) 1381–1384.
[4] P.M. Andersen, P. Nilsson, V. Ala-Hurula, M.L. Keranen, I. Tarvainen, T.
Haltia, L. Nilsson, M. Binzer, L. Forsgren, S.L. Marklund, Amyotrophic
lateral sclerosis associated with homozygosity for an Asp90Ala mutation
in CuZn-superoxide dismutase, Nat. Genet. 10 (1995) 61–66.
[5] M. Jackson, A. Al-Chalabi, Z.E. Enayat, B. Chioza, P.N. Leigh, K.E.
Morrison, Copper/zinc superoxide dismutase 1 and sporadic amyotrophic
lateral sclerosis: analysis of 155 cases and identification of a novel
insertion mutation, Ann. Neurol. 42 (1997) 803–807.
[6] C.T. Jones, P.J. Shaw, G. Chari, D.J. Brock, Identification of a novel exon
4 SOD1 mutation in a sporadic amyotrophic lateral sclerosis patient, Mol.
Cell. Probes 8 (1994) 329–330.
[7] C.T. Jones, R.J. Swingler, D.J. Brock, Identification of a novel SOD1
mutation in an apparently sporadic amyotrophic lateral sclerosis patient
and the detection of Ile113Thr in three others, Hum. Mol. Genet. 3 (1994)
649–650.
[8] C.A.S. Johnston, B.R., M.R. Turner, R. Gray, H.-M. Blunt, D. Butt, M.A.
Ampong, C.E. Shaw, P.N. Leigh, A. Al-Chalabi, Amyotrophic Lateral
Sclerosis in an Urban Setting: a population based study of inner city
London. J. Neurol. (in press).
[9] A.J. Graham, A.M. Macdonald, C.H. Hawkes, British motor neuron
disease twin study, J. Neurol., Neurosurg. Psychiatry 62 (1997) 562–569.
[10] D.S. Falconer, Introduction to Quantitative Genetics, 2nd ed.Longman,
London, 1981.
[11] P. de Knijff, A.M. van den Maagdenberg, R.R. Frants, L.M. Havekes,
Genetic heterogeneity of apolipoprotein E and its influence on plasma
lipid and lipoprotein levels, Hum. Mutat. 4 (1994) 178–194.
[12] E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C.
Gaskell, G.W. Small, A.D. Roses, J.L. Haines, M.A. Pericak-Vance, Gene
dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease
in late onset families, Science 261 (1993) 921–923.
[13] J. Chapman, S. Vinokurov, A. Achiron, D.M. Karussis, K. Mitosek-
Szewczyk, M. Birnbaum, D.M. Michaelson, A.D. Korczyn, APOE
genotype is a major predictor of long-term progression of disability in
MS, Neurology 56 (2001) 312–316.
[14] F.C. Crawford, R.D. Vanderploeg, M.J. Freeman, S. Singh, M. Waisman,
L. Michaels, L. Abdullah, D. Warden, R. Lipsky, A. Salazar, M.J. Mullan,APOE genotype influences acquisition and recall following traumatic
brain injury, Neurology 58 (2002) 1115–1118.
[15] G. Friedman, P. Froom, L. Sazbon, I. Grinblatt, M. Shochina, J. Tsenter,
S. Babaey, B. Yehuda, Z. Groswasser, Apolipoprotein E-epsilon4
genotype predicts a poor outcome in survivors of traumatic brain injury,
Neurology 52 (1999) 244–248.
[16] C.L. Lendon, J.M. Harris, A.L. Pritchard, J.A. Nicoll, G.M. Teasdale, G.
Murray, Genetic variation of the APOE promoter and outcome after head
injury, Neurology 61 (2003) 683–685.
[17] G.M. Teasdale, G.D. Murray, J.A. Nicoll, The association between APOE
epsilon4, age and outcome after head injury: a prospective cohort study,
Brain 128 (2005) 2556–2561.
[18] G.M. Teasdale, J.A. Nicoll, G. Murray, M. Fiddes, Association of
apolipoprotein E polymorphism with outcome after head injury, Lancet
350 (1997) 1069–1071.
[19] S. Mui, G.W. Rebeck, D. McKenna-Yasek, B.T. Hyman, R.H. Brown Jr.,
Apolipoprotein E epsilon 4 allele is not associated with earlier age at
onset in amyotrophic lateral sclerosis, Ann. Neurol. 38 (1995) 460–463.
[20] T. Siddique, M.A. Pericak-Vance, J. Caliendo, S.T. Hong, W.Y. Hung,
J. Kaplan, D. McKenna-Yasek, J.B. Rimmler, P. Sapp, A.M. Saunders,
W.K. Scott, N. Siddique, J.L. Haines, R.H. Brown, Lack of association
between apolipoprotein E genotype and sporadic amyotrophic lateral
sclerosis, Neurogenetics 1 (1998) 213–216.
[21] R. Bachus, S. Bader, R. Gessner, A.C. Ludolph, Lack of association of
apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease,
Ann. Neurol. 41 (1997) 417.
[22] R.G. Smith, L.J. Haverkamp, S. Case, V. Appel, S.H. Appel,
Apolipoprotein E epsilon 4 in bulbar-onset motor neuron disease, Lancet
348 (1996) 334–335.
[23] A. Al-Chalabi, Z.E. Enayat, M.C. Bakker, P.C. Sham, D.M. Ball, C.E.
Shaw, C.M. Lloyd, J.F. Powell, P.N. Leigh, Association of apolipoprotein
E epsilon 4 allele with bulbar-onset motor neuron disease, Lancet 347
(1996) 159–160.
[24] B. Moulard, A. Sefiani, A. Laamri, A. Malafosse, W. Camu,
Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis:
evidence for a major influence on the clinical presentation and prognosis,
J. Neurol. Sci. 139 (1996) 34–37 (Suppl.).
[25] V.E. Drory, M. Birnbaum, A.D. Korczyn, J. Chapman, Association of
APOE epsilon4 allele with survival in amyotrophic lateral sclerosis,
J. Neurol. Sci. 190 (2001) 17–20.
[26] C.a.R. Falk, P., Haplotype relative risks: an easy reliable way to construct
a proper control sample for risk calculations, Ann. Hum. Genet. 51 (1987)
227–233.
[27] R.a.M. Spielman, R.E., W.J. Ewens, Transmission test for linkage
disequilibrium: the insulin gene region and insulin-dependent diabetes
mellitus (IDDM), Am. J. Hum. Genet. 52 (1993) 506–516.
[28] Y.J. Li, M.A. Pericak-Vance, J.L. Haines, N. Siddique, D. McKenna-Yasek,
W.Y. Hung, P. Sapp, C.I. Allen, W. Chen, B. Hosler, A.M. Saunders, L.M.
Dellefave, R.H. Brown Jr., T. Siddique, Apolipoprotein E is associated
with age at onset of amyotrophic lateral sclerosis, Neurogenetics 5 (2004)
209–213.
[29] P.M. Andersen, P. Nilsson, M.L. Keranen, L. Forsgren, J. Hagglund, M.
Karlsborg, L.O. Ronnevi, O. Gredal, S.L. Marklund, Phenotypic
heterogeneity in motor neuron disease patients with CuZn-superoxide
dismutase mutations in Scandinavia, Brain 120 (Pt 10) (1997)
1723–1737.
[30] P.M. Andersen, K.B. Sims, W.W. Xin, R. Kiely, G. O'Neill, J. Ravits, E.
Pioro, Y. Harati, R.D. Brower, J.S. Levine, H.U. Heinicke, W. Seltzer, M.
Boss, R.H. Brown Jr., Sixteen novel mutations in the Cu/Zn superoxide
dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries,
defects and disputes, Amyotroph. Lateral. Scler. Other Mot. Neuron
Disord. 4 (2003) 62–73.
[31] T. Aguirre, G. Matthijs, W. Robberecht, P. Tilkin, J.J. Cassiman,
Mutational analysis of the Cu/Zn superoxide dismutase gene in 23
familial and 69 sporadic cases of amyotrophic lateral sclerosis in
Belgium, Eur. J. Hum. Genet. 7 (1999) 599–602.
[32] W. Robberecht, T. Aguirre, L. Van den Bosch, P. Tilkin, J.J. Cassiman, G.
Matthijs, D90A heterozygosity in the SOD1 gene is associated with
982 C.L. Simpson, A. Al-Chalabi / Biochimica et Biophysica Acta 1762 (2006) 973–985familial and apparently sporadic amyotrophic lateral sclerosis, Neurology
47 (1996) 1336–1339.
[33] A. Al-Chalabi, P.M. Andersen, B. Chioza, C. Shaw, P.C. Sham, W.
Robberecht, G. Matthijs, W. Camu, S.L. Marklund, L. Forsgren, G.
Rouleau, N.G. Laing, P.V. Hurse, T. Siddique, P.N. Leigh, J.F. Powell,
Recessive amyotrophic lateral sclerosis families with the D90A SOD1
mutation share a common founder: evidence for a linked protective factor,
Hum. Mol. Genet. 7 (1998) 2045–2050.
[34] M.E. Cudkowicz, R.H. Brown Jr., An update on superoxide dismutase 1
in familial amyotrophic lateral sclerosis, J. Neurol. Sci. 139 (1996) 10–15
(Suppl.).
[35] M.E. Cudkowicz, D. McKenna-Yasek, P.E. Sapp, W. Chin, B. Geller,
D.L. Hayden, D.A. Schoenfeld, B.A. Hosler, H.R. Horvitz, R.H.
Brown, Epidemiology of mutations in superoxide dismutase in
amyotrophic lateral sclerosis, Ann. Neurol. 41 (1997) 210–221.
[36] L. Regal, L. Vanopdenbosch, P. Tilkin, L. Van den Bosch, V. Thijs, R.
Sciot, W. Robberecht, The G93C mutation in superoxide dismutase 1:
clinicopathologic phenotype and prognosis, Arch. Neurol. 63 (2006)
262–267.
[37] M.J. Parton,W. Broom, P.M.Andersen, A. Al-Chalabi, P. Nigel Leigh, J.F.
Powell, C.E. Shaw, D90A-SOD1 mediated amyotrophic lateral sclerosis:
a single founder for all cases with evidence for a Cis-acting disease
modifier in the recessive haplotype, Hum. Mutat. 20 (2002) 473.
[38] W.J. Broom, C. Russ, P.C. Sapp, D. McKenna-Yasek, B.A. Hosler, P.M.
Andersen, R.H. Brown Jr., Variants in candidate ALS modifier genes
linked to Cu/Zn superoxide dismutase do not explain divergent survival
phenotypes, Neurosci. Lett. 392 (2006) 52–57.
[39] P.A. Jonsson, A. Backstrand, P.M. Andersen, J. Jacobsson, M. Parton, C.
Shaw, R. Swingler, P.J. Shaw, W. Robberecht, A.C. Ludolph, T. Siddique,
V.I. Skvortsova, S.L. Marklund, CuZn-superoxide dismutase in D90A
heterozygotes from recessive and dominant ALS pedigrees, Neurobiol.
Dis. 10 (2002) 327–333.
[40] C.K. Hand, V. Mayeux-Portas, J. Khoris, V. Briolotti, P. Clavelou, W.
Camu, G.A. Rouleau, Compound heterozygous D90A and D96N SOD1
mutations in a recessive amyotrophic lateral sclerosis family, Ann.
Neurol. 49 (2001) 267–271.
[41] R. Adler, K.B. Landa, M. Manthorpe, S. Varon, Cholinergic neurono-
trophic factors: intraocular distribution of trophic activity for ciliary
neurons, Science 204 (1979) 1434–1436.
[42] A.C. Lo, L. Li, R.W. Oppenheim, D. Prevette, L.J. Houenou, Ciliary
neurotrophic factor promotes the survival of spinal sensory neurons
following axotomy but not during the period of programmed cell death,
Exp. Neurol. 134 (1995) 49–55.
[43] M. Sendtner, Y. Arakawa, K.A. Stockli, G.W. Kreutzberg, H. Thoenen,
Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival,
J. Cell Sci., Suppl. 15 (1991) 103–109.
[44] M. Sendtner, G.W. Kreutzberg, H. Thoenen, Ciliary neurotrophic factor
prevents the degeneration of motor neurons after axotomy, Nature 345
(1990) 440–441.
[45] N.Y. Ip, G.D. Yancopoulos, The neurotrophins and CNTF: two families of
collaborative neurotrophic factors, Annu. Rev. Neurosci. 19 (1996) 491–515.
[46] M. Sendtner, H. Schmalbruch, K.A. Stockli, P. Carroll, G.W. Kreutzberg,
H. Thoenen, Ciliary neurotrophic factor prevents degeneration of motor
neurons in mouse mutant progressive motor neuronopathy, Nature 358
(1992) 502–504.
[47] Y. Masu, E. Wolf, B. Holtmann, M. Sendtner, G. Brem, H. Thoenen,
Disruption of the CNTF gene results in motor neuron degeneration,
Nature 365 (1993) 27–32.
[48] J. Gelernter, C. Van Dyck, D.P. van Kammen, R. Malison, L.H. Price, J.F.
Cubells, R. Berman, D.S. Charney, G. Heninger, Ciliary neurotrophic
factor null allele frequencies in schizophrenia, affective disorders, and
Alzheimer's disease, Am. J. Med. Genet. 74 (1997) 497–500.
[49] R.W. Orrell, A.W. King, R.J. Lane, J.S. de Belleroche, Investigation of a
null mutation of the CNTF gene in familial amyotrophic lateral sclerosis,
J. Neurol. Sci. 132 (1995) 126–128.
[50] R. Takahashi, Deficiency of human ciliary neurotropic factor (CNTF) is
not causally related to amyotrophic lateral sclerosis (ALS), Rinsho
Shinkeigaku 35 (1995) 1543–1545.[51] R. Takahashi, H. Yokoji, H. Misawa, M. Hayashi, J. Hu, T. Deguchi, A
null mutation in the human CNTF gene is not causally related to
neurological diseases, Nat. Genet. 7 (1994) 79–84.
[52] R. Giess, R. Goetz, B. Schrank, G. Ochs, M. Sendtner, K. Toyka,
Potential implications of a ciliary neurotrophic factor gene mutation in a
German population of patients with motor neuron disease, Muscle Nerve
21 (1998) 236–238.
[53] A. Al-Chalabi, M.D. Scheffler, B.N. Smith, M.J. Parton, M.E.
Cudkowicz, P.M. Andersen, D.L. Hayden, V.K. Hansen, M.R. Turner,
C.E. Shaw, P.N. Leigh, R.H. Brown Jr., Ciliary neurotrophic factor
genotype does not influence clinical phenotype in amyotrophic lateral
sclerosis, Ann. Neurol. 54 (2003) 130–134.
[54] G.H. Fong, J. Rossant, M. Gertsenstein, M.L. Breitman, Role of the Flt-1
receptor tyrosine kinase in regulating the assembly of vascular
endothelium, Nature 376 (1995) 66–70.
[55] S. Soker, S. Takashima, H.Q. Miao, G. Neufeld, M. Klagsbrun,
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-
specific receptor for vascular endothelial growth factor, Cell 92 (1998)
735–745.
[56] F. Lennmyr, K.A. Ata, K. Funa, Y. Olsson, A. Terent, Expression of
vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and
Flk-1) following permanent and transient occlusion of the middle cerebral
artery in the rat, J. Neuropathol. Exp. Neurol. 57 (1998) 874–882.
[57] K. Yang, C.L. Cepko, Flk-1, a receptor for vascular endothelial growth
factor (VEGF), is expressed by retinal progenitor cells, J. Neurosci. 16
(1996) 6089–6099.
[58] M. Sondell, G. Lundborg, M. Kanje, Vascular endothelial growth factor
has neurotrophic activity and stimulates axonal outgrowth, enhancing cell
survival and Schwann cell proliferation in the peripheral nervous system,
J. Neurosci. 19 (1999) 5731–5740.
[59] B. Oosthuyse, L. Moons, E. Storkebaum, H. Beck, D. Nuyens, K.
Brusselmans, J. Van Dorpe, P. Hellings, M. Gorselink, S. Heymans, G.
Theilmeier, M. Dewerchin, V. Laudenbach, P. Vermylen, H. Raat, T.
Acker, V. Vleminckx, L. Van Den Bosch, N. Cashman, H. Fujisawa, M.R.
Drost, R. Sciot, F. Bruyninckx, D.J. Hicklin, C. Ince, P. Gressens, F.
Lupu, K.H. Plate, W. Robberecht, J.M. Herbert, D. Collen, P. Carmeliet,
Deletion of the hypoxia-response element in the vascular endothelial
growth factor promoter causes motor neuron degeneration, Nat. Genet. 28
(2001) 131–138.
[60] D. Lambrechts, E. Storkebaum, M. Morimoto, J. Del-Favero, F. Desmet,
S.L. Marklund, S. Wyns, V. Thijs, J. Andersson, I. van Marion, A.
Al-Chalabi, S. Bornes, R. Musson, V. Hansen, L. Beckman, R.
Adolfsson, H.S. Pall, H. Prats, S. Vermeire, P. Rutgeerts, S. Katayama,
T. Awata, N. Leigh, L. Lang-Lazdunski, M. Dewerchin, C. Shaw, L.
Moons, R. Vlietinck, K.E.Morrison,W. Robberecht, C. VanBroeckhoven,
D. Collen, P.M. Andersen, P. Carmeliet, VEGF is a modifier of
amyotrophic lateral sclerosis in mice and humans and protects motoneur-
ons against ischemic death, Nat. Genet. 34 (2003) 383–394.
[61] P.W. Van Vught, N.A. Sutedja, J.H. Veldink, B.P. Koeleman, G.J.
Groeneveld, C. Wijmenga, B.M. Uitdehaag, J.M. de Jong, F. Baas, J.H.
Wokke, L.H. Van den Berg, Lack of association between VEGF
polymorphisms and ALS in a Dutch population, Neurology 65 (2005)
1643–1645.
[62] Y. Zhang, H. Zhang, Y. Fu, H. Song, L. Wang, J. Zhang, D. Fan, VEGF
C2578A polymorphism does not contribute to amyotrophic lateral
sclerosis susceptibility in sporadic Chinese patients, Amyotroph. Lateral.
Scler. Other Mot. Neuron Disord. 7 (2006) 119–122.
[63] A. Brockington, J. Kirby, D. Eggitt, E. Schofield, C. Morris, C.E. Lewis,
P.G. Ince, P.J. Shaw, Screening of the regulatory and coding regions of
vascular endothelial growth factor in amyotrophic lateral sclerosis,
Neurogenetics 6 (2005) 101–104.
[64] R. Fernandez-Santiago, M. Sharma, J.C. Mueller, H. Gohlke, T. Illig, J.
Anneser, C. Munch, A. Ludolph, C. Kamm, T. Gasser, Possible gender-
dependent association of vascular endothelial growth factor (VEGF) gene
and ALS, Neurology 66 (2006) 1929–1931.
[65] M.J. Greenway, P.M. Andersen, C. Russ, S. Ennis, S. Cashman, C.
Donaghy, V. Patterson, R. Swingler, D. Kieran, J. Prehn, K.E. Morrison,
A. Green, K.R. Acharya, R.H. Brown, O. Hardiman, ANG mutations
983C.L. Simpson, A. Al-Chalabi / Biochimica et Biophysica Acta 1762 (2006) 973–985segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis,
Nat. Genet. (2006).
[66] M.B. Delisle, S. Carpenter, Neurofibrillary axonal swellings and
amyotrophic lateral sclerosis, J. Neurol. Sci. 63 (1984) 241–250.
[67] S. Matsumoto, H. Kusaka, N. Murakami, Y. Hashizume, H. Okazaki, A.
Hirano, Basophilic inclusions in sporadic juvenile amyotrophic lateral
sclerosis: an immunocytochemical and ultrastructural study, Acta
Neuropathol. (Berl.) 83 (1992) 579–583.
[68] H. Mizusawa, S. Matsumoto, S.H. Yen, A. Hirano, R.R. Rojas-Corona,
H. Donnenfeld, Focal accumulation of phosphorylated neurofilaments
within anterior horn cell in familial amyotrophic lateral sclerosis, Acta
Neuropathol. (Berl.) 79 (1989) 37–43.
[69] D. Troost, P.A. Sillevis Smitt, J.M. de Jong, D.F. Swaab, Neurofilament
and glial alterations in the cerebral cortex in amyotrophic lateral sclerosis,
Acta Neuropathol. (Berl.) 84 (1992) 664–673.
[70] F. Cote, J.F. Collard, J.P. Julien, Progressive neuronopathy in transgenic
mice expressing the human neurofilament heavy gene: a mouse model of
amyotrophic lateral sclerosis, Cell 73 (1993) 35–46.
[71] Z. Xu, L.C. Cork, J.W. Griffin, D.W. Cleveland, Increased expression of
neurofilament subunit NF-L produces morphological alterations that
resemble the pathology of human motor neuron disease, Cell 73 (1993)
23–33.
[72] T.L. Williamson, L.I. Bruijn, Q. Zhu, K.L. Anderson, S.D. Anderson, J.P.
Julien, D.W. Cleveland, Absence of neurofilaments reduces the selective
vulnerability of motor neurons and slows disease caused by a familial
amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant, Proc.
Natl. Acad. Sci. U. S. A. 95 (1998) 9631–9636.
[73] S. Couillard-Despres, Q. Zhu, P.C. Wong, D.L. Price, D.W. Cleveland,
J.P. Julien, Protective effect of neurofilament heavy gene overexpres-
sion in motor neuron disease induced by mutant superoxide dismutase,
Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9626–9630.
[74] J. Kong, Z. Xu, Overexpression of neurofilament subunit NF-L and NF-H
extends survival of a mouse model for amyotrophic lateral sclerosis,
Neurosci. Lett. 281 (2000) 72–74.
[75] S. Couillard-Despres, J. Meier, J.P. Julien, Extra axonal neurofilaments
do not exacerbate disease caused by mutant Cu,Zn superoxide dismutase,
Neurobiol. Dis. 7 (2000) 462–470.
[76] D.A. Figlewicz, G.A. Rouleau, A. Krizus, J.P. Julien, Polymorphism in
the multi-phosphorylation domain of the human neurofilament heavy-
subunit-encoding gene, Gene 132 (1993) 297–300.
[77] D.A. Figlewicz, A. Krizus, M.G. Martinoli, V. Meininger, M. Dib, G.
A. Rouleau, J.P. Julien, Variants of the heavy neurofilament subunit
are associated with the development of amyotrophic lateral sclerosis,
Hum. Mol. Genet. 3 (1994) 1757–1761.
[78] K. Rooke, D.A. Figlewicz, F.Y. Han, G.A. Rouleau, Analysis of the KSP
repeat of the neurofilament heavy subunit in familiar amyotrophic lateral
sclerosis, Neurology 46 (1996) 789–790.
[79] J.D. Vechio, L.I. Bruijn, Z. Xu, R.H. Brown Jr., D.W. Cleveland,
Sequence variants in human neurofilament proteins: absence of linkage to
familial amyotrophic lateral sclerosis, Ann. Neurol. 40 (1996) 603–610.
[80] A. Al-Chalabi, P.M. Andersen, P. Nilsson, B. Chioza, J.L. Andersson, C.
Russ, C.E. Shaw, J.F. Powell, P.N. Leigh, Deletions of the heavy
neurofilament subunit tail in amyotrophic lateral sclerosis, Hum. Mol.
Genet. 8 (1999) 157–164.
[81] J. Tomkins, P. Usher, J.Y. Slade, P.G. Ince, A. Curtis, K. Bushby, P.J.
Shaw, Novel insertion in the KSP region of the neurofilament heavy gene
in amyotrophic lateral sclerosis (ALS), NeuroReport 9 (1998)
3967–3970.
[82] M.L. Garcia, A.B. Singleton, D. Hernandez, C.M. Ward, C. Evey, P.A.
Sapp, J. Hardy, R.H. Brown Jr., D.W. Cleveland, Mutations in
neurofilament genes are not a significant primary cause of non-SOD1-
mediated amyotrophic lateral sclerosis, Neurobiol. Dis. 21 (2006)
102–109.
[83] D.M. Georgiou, J. Zidar, M. Korosec, L.T. Middleton, T. Kyriakides, K.
Christodoulou, A novel NF-L mutation Pro22Ser is associated with
CMT2 in a large Slovenian family, Neurogenetics 4 (2002) 93–96.
[84] I.V. Mersiyanova, A.V. Perepelov, A.V. Polyakov, V.F. Sitnikov, E.L.
Dadali, R.B. Oparin, A.N. Petrin, O.V. Evgrafov, A new variant ofCharcot–Marie–Tooth disease type 2 is probably the result of a mutation
in the neurofilament-light gene, Am. J. Hum. Genet. 67 (2000) 37–46.
[85] M.M. Portier, B. de Nechaud, F. Gros, Peripherin, a new member of the
intermediate filament protein family, Dev. Neurosci. 6 (1983) 335–344.
[86] F. Gros-Louis, R. Lariviere, G. Gowing, S. Laurent, W. Camu, J.P.
Bouchard, V. Meininger, G.A. Rouleau, J.P. Julien, A frameshift deletion
in peripherin gene associated with amyotrophic lateral sclerosis, J. Biol.
Chem. 279 (2004) 45951–45956.
[87] C.L. Leung, C.Z. He, P. Kaufmann, S.S. Chin, A. Naini, R.K. Liem, H.
Mitsumoto, A.P. Hays, A pathogenic peripherin gene mutation in a
patient with amyotrophic lateral sclerosis, Brain Pathol. 14 (2004)
290–296.
[88] T. Murakami, I. Nagano, T. Hayashi, Y. Manabe, M. Shoji, Y. Setoguchi,
K. Abe, Impaired retrograde axonal transport of adenovirus-mediated E.
coli LacZ gene in the mice carrying mutant SOD1 gene, Neurosci. Lett.
308 (2001) 149–152.
[89] A. Harada, Y. Takei, Y. Kanai, Y. Tanaka, S. Nonaka, N. Hirokawa, Golgi
vesiculation and lysosome dispersion in cells lacking cytoplasmic dynein,
J. Cell Biol. 141 (1998) 51–59.
[90] M. Hafezparast, R. Klocke, C. Ruhrberg, A. Marquardt, A. Ahmad-
Annuar, S. Bowen, G. Lalli, A.S. Witherden, H. Hummerich, S.
Nicholson, P.J. Morgan, R. Oozageer, J.V. Priestley, S. Averill, V.R.
King, S. Ball, J. Peters, T. Toda, A. Yamamoto, Y. Hiraoka, M. Augustin,
D. Korthaus, S. Wattler, P. Wabnitz, C. Dickneite, S. Lampel, F. Boehme,
G. Peraus, A. Popp, M. Rudelius, J. Schlegel, H. Fuchs, M. Hrabe de
Angelis, G. Schiavo, D.T. Shima, A.P. Russ, G. Stumm, J.E. Martin, E.M.
Fisher, Mutations in dynein link motor neuron degeneration to defects in
retrograde transport, Science 300 (2003) 808–812.
[91] A. Ahmad-Annuar, P. Shah, M. Hafezparast, H. Hummerich, A.S.
Witherden, K.E. Morrison, P.J. Shaw, J. Kirby, T.T. Warner, A. Crosby, C.
Proukakis, P. Wilkinson, R.W. Orrell, L. Bradley, J.E. Martin, E.M.
Fisher, No association with common Caucasian genotypes in exons 8, 13
and 14 of the human cytoplasmic dynein heavy chain gene (DNCHC1)
and familial motor neuron disorders, Amyotroph. Lateral. Scler. Other
Mot. Neuron Disord. 4 (2003) 150–157.
[92] L.A. Ligon, B.H. LaMonte, K.E. Wallace, N. Weber, R.G. Kalb, E.L.
Holzbaur, Mutant superoxide dismutase disrupts cytoplasmic dynein in
motor neurons, NeuroReport 16 (2005) 533–536.
[93] B.A. Eaton, R.D. Fetter, G.W. Davis, Dynactin is necessary for synapse
stabilization, Neuron 34 (2002) 729–741.
[94] B.H. LaMonte, K.E. Wallace, B.A. Holloway, S.S. Shelly, J. Ascano, M.
Tokito, T. Van Winkle, D.S. Howland, E.L. Holzbaur, Disruption of
dynein/dynactin inhibits axonal transport in motor neurons causing late-
onset progressive degeneration, Neuron 34 (2002) 715–727.
[95] C. Munch, R. Sedlmeier, T. Meyer, V. Homberg, A.D. Sperfeld, A. Kurt,
J. Prudlo, G. Peraus, C.O. Hanemann, G. Stumm, A.C. Ludolph, Point
mutations of the p150 subunit of dynactin (DCTN1) gene in ALS,
Neurology 63 (2004) 724–726.
[96] I. Puls, C. Jonnakuty, B.H. LaMonte, E.L. Holzbaur, M. Tokito, E. Mann,
M.K. Floeter, K. Bidus, D. Drayna, S.J. Oh, R.H. Brown Jr., C.L. Ludlow,
K.H. Fischbeck, Mutant dynactin in motor neuron disease, Nat. Genet. 33
(2003) 455–456.
[97] C. Munch, A. Rosenbohm, A.D. Sperfeld, I. Uttner, S. Reske, B.J.
Krause, R. Sedlmeier, T. Meyer, C.O. Hanemann, G. Stumm, A.C.
Ludolph, Heterozygous R1101Kmutation of the DCTN1 gene in a family
with ALS and FTD, Ann. Neurol. 58 (2005) 777–780.
[98] P. Corcia, V. Mayeux-Portas, J. Khoris, B. de Toffol, A. Autret, J.P. Muh,
W. Camu, C. Andres, Abnormal SMN1 gene copy number is a
susceptibility factor for amyotrophic lateral sclerosis, Ann. Neurol. 51
(2002) 243–246.
[99] M. Jackson, K.E. Morrison, A. Al-Chalabi, M. Bakker, P.N. Leigh,
Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis:
homozygous NAIP deletion in a sporadic case, Ann. Neurol. 39 (1996)
796–800.
[100] B. Moulard, F. Salachas, B. Chassande, V. Briolotti, V. Meininger, A.
Malafosse, W. Camu, Association between centromeric deletions of the
SMN gene and sporadic adult-onset lower motor neuron disease, Ann.
Neurol. 43 (1998) 640–644.
984 C.L. Simpson, A. Al-Chalabi / Biochimica et Biophysica Acta 1762 (2006) 973–985[101] R.W. Orrell, J.J. Habgood, J.S. de Belleroche, R.J. Lane, The relationship
of spinal muscular atrophy to motor neuron disease: investigation of
SMN and NAIP gene deletions in sporadic and familial ALS, J. Neurol.
Sci. 145 (1997) 55–61.
[102] J.S. Parboosingh, V.Meininger, D.McKenna-Yasek, R.H. Brown Jr., G.A.
Rouleau, Deletions causing spinal muscular atrophy do not predispose to
amyotrophic lateral sclerosis, Arch. Neurol. 56 (1999) 710–712.
[103] J. Gamez, M.J. Barcelo, X. Munoz, F. Carmona, I. Cusco, M. Baiget, C.
Cervera, E.F. Tizzano, Survival and respiratory decline are not related to
homozygous SMN2 deletions in ALS patients, Neurology 59 (2002)
1456–1460.
[104] J.H. Veldink, L.H. van den Berg, J.M. Cobben, R.P. Stulp, J.M. De Jong,
O.J. Vogels, F. Baas, J.H. Wokke, H. Scheffer, Homozygous deletion of
the survival motor neuron 2 gene is a prognostic factor in sporadic ALS,
Neurology 56 (2001) 749–752.
[105] J.H. Veldink, S. Kalmijn, A.H. Van der Hout, H.H. Lemmink, G.J.
Groeneveld, C. Lummen, H. Scheffer, J.H. Wokke, L.H. Van den Berg,
SMN genotypes producing less SMN protein increase susceptibility to
and severity of sporadic ALS, Neurology 65 (2005) 820–825.
[106] C.B. Kunst, L. Messer, J. Gordon, J. Haines, D. Patterson, Genetic
mapping of a mouse modifier gene that can prevent ALS onset, Genomics
70 (2000) 181–189.
[107] F. Kamel, D.M. Umbach, T.A. Lehman, L.P. Park, T.L. Munsat, J.M.
Shefner, D.P. Sandler, H. Hu, J.A. Taylor, Amyotrophic lateral sclerosis,
lead, and genetic susceptibility: polymorphisms in the delta-aminolevu-
linic acid dehydratase and vitamin D receptor genes, Environ. Health
Perspect. 111 (2003) 1335–1339.
[108] F. Kamel, D.M. Umbach, T.L. Munsat, J.M. Shefner, H. Hu, D.P. Sandler,
Lead exposure and amyotrophic lateral sclerosis, Epidemiology 13
(2002) 311–319.
[109] C.K. Hand, R.S. Devon, F. Gros-Louis, D. Rochefort, J. Khoris, V.
Meininger, J.P. Bouchard, W. Camu, M.R. Hayden, G.A. Rouleau,
Mutation screening of the ALS2 gene in sporadic and familial
amyotrophic lateral sclerosis, Arch. Neurol. 60 (2003) 1768–1771.
[110] S. Hadano, C.K. Hand, H. Osuga, Y. Yanagisawa, A. Otomo, R.S. Devon,
N. Miyamoto, J. Showguchi-Miyata, Y. Okada, R. Singaraja, D.A.
Figlewicz, T. Kwiatkowski, B.A. Hosler, T. Sagie, J. Skaug, J. Nasir, R.H.
Brown Jr., S.W. Scherer, G.A. Rouleau, M.R. Hayden, J.E. Ikeda, A gene
encoding a putative GTPase regulator is mutated in familial amyotrophic
lateral sclerosis 2, Nat. Genet. 29 (2001) 166–173.
[111] Y. Yang, A. Hentati, H.X. Deng, O. Dabbagh, T. Sasaki, M. Hirano, W.Y.
Hung, K. Ouahchi, J. Yan, A.C. Azim, N. Cole, G. Gascon, A. Yagmour,
M. Ben-Hamida, M. Pericak-Vance, F. Hentati, T. Siddique, The gene
encoding alsin, a protein with three guanine-nucleotide exchange factor
domains, is mutated in a form of recessive amyotrophic lateral sclerosis,
Nat. Genet. 29 (2001) 160–165.
[112] B.A. Hosler, P.C. Sapp, R. Berger, G. O'Neill, K. Bejaoui, M.B. Hamida,
F. Hentati, W. Chin, D. McKenna-Yasek, J.L. Haines, D. Patterson, H.R.
Horvitz, R.H. Brown Jr., C.B. Day, Refined mapping and characterization
of the recessive familial amyotrophic lateral sclerosis locus (ALS2) on
chromosome 2q33, Neurogenetics 2 (1998) 34–42.
[113] A. Hentati, K. Bejaoui, M.A. Pericak-Vance, F. Hentati, M.C. Speer, W.Y.
Hung, D.A. Figlewicz, J. Haines, J. Rimmler, C. Ben Hamida, et al.,
Linkage of recessive familial amyotrophic lateral sclerosis to chromo-
some 2q33–q35, Nat. Genet. 7 (1994) 425–428.
[114] M.J. Greenway, M.D. Alexander, S. Ennis, B.J. Traynor, B. Corr, E.
Frost, A. Green, O. Hardiman, A novel candidate region for ALS on
chromosome 14q11.2, Neurology 63 (2004) 1936–1938.
[115] C. Hayward, S. Colville, R.J. Swingler, D.J. Brock, Molecular genetic
analysis of the APEX nuclease gene in amyotrophic lateral sclerosis,
Neurology 52 (1999) 1899–1901.
[116] O. Garofalo, D.A. Figlewicz, P.N. Leigh, J.F. Powell, V. Meininger, M.
Dib, G.A. Rouleau, Androgen receptor gene polymorphisms in
amyotrophic lateral sclerosis, Neuromuscul. Disord. 3 (1993) 195–199.
[117] A.N. Silahtaroglu, K. Brondum-Nielsen, O. Gredal, L. Werdelin, M.
Panas, M.B. Petersen, N. Tommerup, Z. Tumer, Human CCS gene:
genomic organization and exclusion as a candidate for amyotrophic
lateral sclerosis (ALS), BMC Genet. 3 (2002) 5.[118] T.M. DeChiara, R. Vejsada, W.T. Poueymirou, A. Acheson, C. Suri, J.C.
Conover, B. Friedman, J. McClain, L. Pan, N. Stahl, et al., Mice lacking
the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor
neuron deficits at birth, Cell 83 (1995) 313–322.
[119] R. Giess, B. Holtmann, M. Braga, T. Grimm, B. Muller-Myhsok, K.V.
Toyka, M. Sendtner, Early onset of severe familial amyotrophic lateral
sclerosis with a SOD-1 mutation: potential impact of CNTF as a
candidate modifier gene, Am. J. Hum. Genet. 70 (2002) 1277–1286.
[120] D.J. Nicholl, P. Bennett, L. Hiller, V. Bonifati, N. Vanacore, G. Fabbrini,
R. Marconi, C. Colosimo, P. Lamberti, F. Stocchi, U. Bonuccelli, P.
Vieregge, D.B. Ramsden, G. Meco, A.C. Williams, A study of five
candidate genes in Parkinson's disease and related neurodegenerative
disorders. European Study Group on Atypical Parkinsonism, Neurology
53 (1999) 1415–1421.
[121] M.A. Siddons, S.M. Pickering-Brown, D.M. Mann, F. Owen, P.N.
Cooper, Debrisoquine hydroxylase gene polymorphism frequencies in
patients with amyotrophic lateral sclerosis, Neurosci. Lett. 208 (1996)
65–68.
[122] J.M. Flowers, J.F. Powell, P.N. Leigh, P. Andersen, C.E. Shaw, Intron 7
retention and exon 9 skipping EAAT2 mRNA variants are not associated
with amyotrophic lateral sclerosis, Ann. Neurol. 49 (2001) 643–649.
[123] L.S. Honig, D.D. Chambliss, E.H. Bigio, S.L. Carroll, J.L. Elliott,
Glutamate transporter EAAT2 splice variants occur not only in ALS, but
also in AD and controls, Neurology 55 (2000) 1082–1088.
[124] M. Jackson, G. Steers, P.N. Leigh, K.E. Morrison, Polymorphisms in the
glutamate transporter gene EAAT2 in European ALS patients, J. Neurol.
246 (1999) 1140–1144.
[125] T. Meyer, A. Fromm, C. Munch, B. Schwalenstocker, A.E. Fray, P.G.
Ince, S. Stamm, G. Gron, A.C. Ludolph, P.J. Shaw, The RNA of the
glutamate transporter EAAT2 is variably spliced in amyotrophic lateral
sclerosis and normal individuals, J. Neurol. Sci. 170 (1999) 45–50.
[126] T. Meyer, C. Munch, H. Volkel, P. Booms, A.C. Ludolph, The EAAT2
(GLT-1) gene in motor neuron disease: absence of mutations in
amyotrophic lateral sclerosis and a point mutation in patients with
hereditary spastic paraplegia, J. Neurol., Neurosurg. Psychiatry 65 (1998)
594–596.
[127] M. Aoki, C.L. Lin, J.D. Rothstein, B.A. Geller, B.A. Hosler, T.L. Munsat,
H.R. Horvitz, R.H. Brown Jr., Mutations in the glutamate transporter
EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic
lateral sclerosis, Ann. Neurol. 43 (1998) 645–653.
[128] C.L. Lin, L.A. Bristol, L. Jin, M. Dykes-Hoberg, T. Crawford, L.
Clawson, J.D. Rothstein, Aberrant RNA processing in a neurodegenera-
tive disease: the cause for absent EAAT2, a glutamate transporter, in
amyotrophic lateral sclerosis, Neuron 20 (1998) 589–602.
[129] V.E. Drory, M. Birnbaum, L. Peleg, B. Goldman, A.D. Korczyn,
Hexosaminidase A deficiency is an uncommon cause of a syndrome
mimicking amyotrophic lateral sclerosis, Muscle Nerve 28 (2003)
109–112.
[130] X.S. Wang, S. Lee, Z. Simmons, P. Boyer, K. Scott, W. Liu, J. Connor,
Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis
and related cellular consequences, J. Neurol. Sci. 227 (2004) 27–33.
[131] A.A. Yen, E.P. Simpson, J.S. Henkel, D.R. Beers, S.H. Appel, HFE
mutations are not strongly associated with sporadic ALS, Neurology 62
(2004) 1611–1612.
[132] R. Giess, M. Beck, R. Goetz, R.M. Nitsch, K.V. Toyka, M. Sendtner,
Potential role of LIF as a modifier gene in the pathogenesis of
amyotrophic lateral sclerosis, Neurology 54 (2000) 1003–1005.
[133] M.A. Meyer, N.T. Potter, Sporadic ALS and chromosome 22: evidence
for a possible neurofilament gene defect, Muscle Nerve 18 (1995)
536–539.
[134] B.A. Chioza, A. Ujfalusy, K. Csiszar, P.N. Leigh, J.F. Powell, A.
Radunovic, Mutations in the lysyl oxidase gene are not associated with
amyotrophic lateral sclerosis, Amyotroph. Lateral. Scler. Other Mot.
Neuron Disord. 2 (2001) 93–97.
[135] S. Orru, V. Mascia, M. Casula, E. Giuressi, A. Loizedda, C. Carcassi, M.
Giagheddu, L. Contu, Association of monoamine oxidase B alleles with
age at onset in amyotrophic lateral sclerosis, Neuromuscul. Disord. 9
(1999) 593–597.
985C.L. Simpson, A. Al-Chalabi / Biochimica et Biophysica Acta 1762 (2006) 973–985[136] A. Kowalska, M. Konagaya, M. Sakai, Y. Hashizume, T. Tabira, Familial
amyotrophic lateral sclerosis and parkinsonism–dementia complex-
tauopathy without mutations in the tau gene? Folia Neuropathol. 41
(2003) 59–64.
[137] P. Poorkaj, D. Tsuang, E. Wijsman, E. Steinbart, R.M. Garruto, U.K.
Craig, N.H. Chapman, L. Anderson, T.D. Bird, C.C. Plato, D.P. Perl, W.
Weiderholt, D. Galasko, G.D. Schellenberg, TAU as a susceptibility gene
for amyotropic lateral sclerosis–parkinsonism dementia complex of
Guam, Arch. Neurol. 58 (2001) 1871–1878.
[138] G.K. Dhaliwal, R.P. Grewal, Mitochondrial DNA deletion mutation
levels are elevated in ALS brains, NeuroReport 11 (2000) 2507–2509.
[139] C.D. Gajewski, M.T. Lin, M.E. Cudkowicz, M.F. Beal, G. Manfredi,
Mitochondrial DNA from platelets of sporadic ALS patients restores
normal respiratory functions in rho(0) cells, Exp. Neurol. 179 (2003)
229–235.
[140] C. Mawrin, E. Kirches, K. Dietzmann, Single-cell analysis of mtDNA in
amyotrophic lateral sclerosis: towards the characterization of individual
neurons in neurodegenerative disorders, Pathol. Res. Pract. 199 (2003)
415–418.
[141] C. Mawrin, E. Kirches, G. Krause, F.R. Wiedemann, C.K. Vorwerk, B.
Bogerts, H.U. Schildhaus, K. Dietzmann, R. Schneider-Stock, Single-cell
analysis of mtDNA deletion levels in sporadic amyotrophic lateral
sclerosis, NeuroReport 15 (2004) 939–943.
[142] L.S. Ro, S.L. Lai, C.M. Chen, S.T. Chen, Deleted 4977-bp mitochondrial
DNAmutation is associated with sporadic amyotrophic lateral sclerosis: a
hospital-based case-control study, Muscle Nerve 28 (2003) 737–743.
[143] R.H. Swerdlow, J.K. Parks, D.S. Cassarino, P.A. Trimmer, S.W.Miller, D.J.
Maguire, J.P. Sheehan, R.S.Maguire, G. Pattee, V.C. Juel, L.H. Phillips, J.B.
Tuttle, J.P. Bennett Jr., R.E.Davis,W.D. Parker Jr.,Mitochondria in sporadic
amyotrophic lateral sclerosis, Exp. Neurol. 153 (1998) 135–142.
[144] F.R. Wiedemann, G. Manfredi, C. Mawrin, M.F. Beal, E.A. Schon,
Mitochondrial DNA and respiratory chain function in spinal cords of
ALS patients, J. Neurochem. 80 (2002) 616–625.
[145] F.H. Lin, R. Lin, H.M. Wisniewski, Y.W. Hwang, I. Grundke-Iqbal, G.
Healy-Louie, K. Iqbal, Detection of point mutations in codon 331 of
mitochondrial NADH dehydrogenase subunit 2 in Alzheimer's brains,
Biochem. Biophys. Res. Commun. 182 (1992) 238–246.
[146] J.P. Julien, F. Cote, J.F. Collard, Mice overexpressing the human
neurofilament heavy gene as a model of ALS, Neurobiol. Aging 16
(1995) 487–490 (discussion 490–2).[147] M. Panas, G. Karadima, N. Kalfakis, O. Psarrou, P. Floroskoufi, A.
Kladi, M.B. Petersen, D. Vassilopoulos, Genotyping of presenilin-1
polymorphism in amyotrophic lateral sclerosis, J. Neurol. 247 (2000)
940–942.
[148] R. Saunderson, B. Yu, R.J. Trent, R. Pamphlett, A polymorphism in the
poliovirus receptor gene differs in motor neuron disease, NeuroReport 15
(2004) 383–386.
[149] . Y.Z. Chen, C.L. Bennett, H.M. Huynh, I.P. Blair, I. Puls, J. Irobi, I.
Dierick, A. Abel, M.L. Kennerson, B.A. Rabin, G.A. Nicholson, M.
Auer-Grumbach, K. Wagner, P. De Jonghe, J.W. Griffin, K.H. Fischbeck,
V. Timmerman, D.R. Cornblath, P.F. Chance, DNA/RNA helicase gene
mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4),
Am. J. Hum. Genet. 74 (2004) 1128–1135.
[150] P. Corcia, J. Khoris, P. Couratier, V. Mayeux-Portas, E. Bieth, B.
De Toffol, A. Autret, J.P. Muh, C. Andres, W. Camu, SMN1 gene
study in three families in which ALS and spinal muscular atrophy
co-exist, Neurology 59 (2002) 1464–1466.
[151] C.J. McDermott, D. Roberts, J. Tomkins, K.M. Bushby, P.J. Shaw,
Spastin and paraplegin gene analysis in selected cases of motor neurone
disease (MND), Amyotroph. Lateral. Scler. Other Mot. Neuron Disord. 4
(2003) 96–99.
[152] T. Meyer, A. Schwan, J.S. Dullinger, J. Brocke, K.T. Hoffmann, C.H.
Nolte, A. Hopt, U. Kopp, P. Andersen, J.T. Epplen, P. Linke, Early-onset
ALS with long-term survival associated with spastin gene mutation,
Neurology 65 (2005) 141–143.
[153] J.M. Flowers, P.N. Leigh, A.M. Davies, N.N. Ninkina, V.L. Buchman, J.
Vaughan, N.W. Wood, J.F. Powell, Mutations in the gene encoding
human persyn are not associated with amyotrophic lateral sclerosis or
familial Parkinson's disease, Neurosci. Lett. 274 (1999) 21–24.
[154] J. Tomkins, S.J. Banner, C.J. McDermott, P.J. Shaw, Mutation screening
of manganese superoxide dismutase in amyotrophic lateral sclerosis,
NeuroReport 12 (2001) 2319–2322.
[155] A.L. Nishimura, M. Mitne-Neto, H.C. Silva, A. Richieri-Costa, S.
Middleton, D. Cascio, F. Kok, J.R. Oliveira, T. Gillingwater, J. Webb, P.
Skehel, M. Zatz, A mutation in the vesicle-trafficking protein VAPB
causes late-onset spinal muscular atrophy and amyotrophic lateral
sclerosis, Am. J. Hum. Genet. 75 (2004) 822–831.
[156] P.D. Terry, F. Kamel, D.M. Umbach, T.A. Lehman, H. Hu, D.P. Sandler,
J.A. Taylor, VEGF promoter haplotype and amyotrophic lateral sclerosis
(ALS), J. Neurogenet. 18 (2004) 429–434.
